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Abstract: Glucocorticoids (GC)-induced osteoporosis (GIOP) is the most common cause of 
secondary osteoporosis, which leads to an increased fracture risk in patients. The normal bone 
turnover depends on a balance between osteoblasts and osteoclasts activity and GC can cause 
a rapid bone loss, decreasing bone formation and increasing bone resorption. The decreased 
bone formation is mainly due to the GC-induced apoptosis of both osteoblasts and osteocytes, 
while the increased bone resorption is due to the increased life-span of pre-existing osteoclasts. 
Bisphosphonates are clearly effective in preventing and treating GIOP but anabolic therapeutic 
strategies are the new promising therapeutic alternative. Experimental and clinical studies indi-
cate that teriparatide, the active (1–34) parathyroid hormone (PTH) molecule, is efﬁ  cacious for 
the treatment of GIOP, being able to induce an increase in bone mass in these patients. Intermit-
tent administration of human PTH (1–34) stimulates bone formation by increasing osteoblast 
number. Additionally, human PTH (1–34) modulates the level and/or activity of locally produced 
growth factors and cytokines. Teriparatide has been demonstrated in several clinical studies to 
signiﬁ  cantly decrease the incidence of fractures in patients affected by GIOP. It has recently 
received an indication for GIOP and its label indication has also been expanded.
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Introduction
Early last century Cushing described the negative effect of hypercotisolism on the 
skeleton.1 Nowadays secondary forms, due to pharmacological use of glucocorticoids 
(GC), are the most frequent forms of an excess of these hormones.2–6 GC are the most 
widely used therapy in medicine and long-term use is characterized by a signiﬁ  cant 
alteration of bone tissue, named GC-induced osteoporosis (GIOP), which is a metabolic 
bone disease characterized by decreased skeletal strength with an increased fracture 
risk.4 The GC-induced bone loss is dose-dependent, but it can also be present with 
long-term low dosage treatments.3–6 Indeed, the loss of bone mass occurs in a bipha-
sic manner with a fast decrease at the beginning of therapy (loss of 12% in the ﬁ  rst 
year) and a slower decrease after then (3%).7–8 GIOP must be considered a serious 
pathological condition because of the high number of patients who use these molecules 
to treat many different chronic diseases.8
As ﬁ  rst described by Cushing, GIOP affects both trabecular and cortical bone and 
a vertebral fracture can be the ﬁ  rst symptom of the disease.1,9,10.
Although the clinical manifestations of GC therapy have been known since the 
early 20th century,1–6 the cellular and molecular mechanisms of skeletal alterations are 
not yet fully known. Some data suggest that alterations in hormonal levels might play 
a role in the calcium–phosphorus homeostasis (Table 1); however, GC exert a direct 
receptor-mediated effect on bone cells, leading to an altered bone remodeling.11
Indeed, bone tissue is a metabolically active organ undergoing continuous 
remodeling throughout life, which serves to adjust bone architecture to meet mechanical Therapeutics and Clinical Risk Management 2009:5 306
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needs, to repair microdamage of bone matrix, and to prevent 
accumulation of old and damaged bone. Additionally, bone 
remodeling plays an important role in plasma calcium 
homeostasis. As noted, this process involves the removal 
of damaged bone tissue by osteoclasts followed by the 
formation of bone matrix through the osteoblasts,11 derived 
from a mesenchymal cell progenitor, unique for adypocites, 
chondrocytes and muscle cells.
The regulation of bone remodeling is known to be 
both systemic and local, and GC dramatically alter these 
sophisticated mechanisms, decreasing bone formation and 
increasing resorption, with a net decrease in the number and 
in the perimeter of the trabeculae.12,13
Molecular and cellular mechanisms
GC are steroidal hormones which act as ligand-induced 
transcription factors by binding intracellular receptors, 
which leads to conformational changes followed by nuclear 
translocation of hormone-bound receptor.14 These ligand-
induced intracellular events lead to the induction/repression 
of speciﬁ  c target genes14,15 and speciﬁ  c biological effects.
Some data indicate that these hormones, as also described 
for estrogens,16 induce nongenomic effects by a putative 
membrane receptor, which activates intracellular kinases 
such as the extracellular signal-regulated kinases (ERKs), 
c-Jun N-terminal kinase (JNK), and proline rich tyrosine 
kinase 2 (Pyk2).17,18 Because GC receptors are present on 
both osteoblasts and osteoclasts, bone tissue is a target for 
GC.19,20 Furthermore, these steroids can induce different 
effects on skeletal tissue depending on their concentration, 
time of exposure, and cell differentiation.20–25
The ﬁ  rst rapid effect induced by GC exposure is a rapid 
bone loss due to osteoclast activation. GC can modulate 
osteoclast activity directly: short-term exposure to GC 
induces an increase in the number and activity of osteoclasts 
as well as a decrease in cell apoptosis and a net increase in 
osteoclast life-span.5,6,25 GC can also modulate bone resorbing 
cells through an osteoblast-mediated mechanism by stimu-
lating the synthesis of both RANKL (receptor activator for 
nuclear factor κ B ligand) and granulocyte colony-stimulating 
factor (G-CSF) and by decreasing osteoprotegerin (OPG) 
expression.26
Long-term GC exposure or exposure to high dosages 
induce further negative effects, such as osteoblast apoptosis, 
decreased osteoblast proliferation and differentiation, and 
osteocytes apoptosis, with a consequent signiﬁ  cant decrease 
in bone formation.27–29
Interestingly, low concentrations of GC stimulate both 
osteoblasts proliferation and differentiation by speciﬁ  c genes 
activation such as bone morphogenetic proteins (BMPs), 
the transcription factor Cbfa-1, transforming growth factor 
beta (TGF-β) and insulin-like growth factor I (IGF-I). How-
ever, an alteration of these mechanisms, induced by either 
high concentration or long-term exposure, strongly inhibits 
mesenchymal cells differentiation, osteoblasts prolifera-
tion and activity, and also increases both osteoblasts and 
osteocytes apoptosis.5,12,13,24–29 These signiﬁ  cant changes in 
bone homeostasis and remodeling, as outlined in Figure 1, 
lead to bone loss, osteopenia and consequently an increase 
in fragility fracture risk.
Therapeutical perspectives
As mentioned above, because GIOP is a severe condition 
which leads to an increased fracture risk within the ﬁ  rst 
months of therapy,30 efﬁ  cacious therapies are needed to 
counter their deleterious effects on the skeleton. Although 
bisphosphonates have been demonstrated to be an efﬁ  cacious 
therapy for both prevention and cure of GIOP,31–33 the new 
bone anabolic agent teriparatide is a highly promising and 
interesting molecule for the treatment of GIOP.
Mechanisms of action 
of teriparatide
The beneﬁ  cial effects of daily injection of human parathyroid 
hormone (PTH) amino-terminal peptide 1–34, teriparatide, 
have been shown in randomized, placebo-controlled trials in 
postmenopausal women, and in elderly men and in women 
with GIOP.34–36
Osteoblasts, bone lining cells, and bone marrow stromal 
cells have PTH receptors, and intermittent PTH stimulates 
these cells through the modulation of cAMP concentrations and 
Table 1 Mechanisms involved in glucocorticoids (GC)-induced 
osteoporosis
Direct effects on bone cells
  Decrease of osteoblasts proliferation and activity
  Increase of osteoblast and osteocytes apoptosis
  Increase of osteoclasts life-span and activity
Effects on phosphorus and calcium homeostasis
  Decrease of intestinal calcium absorption
  Increase of urinary calcium excretion
Effects on pituitary-gonads-adrenal axis
  Decrease of pituitary gonadotrophins
  Decrease of estradiol and testosterone synthesis and secretion
  Inhibition of androstenedione synthesis and secretion
Effects on hormones modulating calcium-phosphorus homeostasis
  Increase of PTH synthesis and secretion
  Increase of PTH and Vitamin D sensitivity (hypothetical)Therapeutics and Clinical Risk Management 2009:5 307
Management of glucocorticoids-induced osteoporosis
cAMP-dependent protein kinase A.38 The PTH receptor also 
activates the calcium protein kinase C pathway, stimulating 
proliferation of cells in the osteoblastic lineage.39,40
The new molecule teriparatide exerts its anabolic effect 
at least in part by stimulating the MAPK pathway41 and, thus, 
modulating the differentiation, proliferation, and activity of the 
osteoblasts pool,37,41,42 stimulating differentiation and activation 
of quiescent lining cells,41,42 increasing the lifespan of osteo-
blasts and osteocytes by inhibiting their apoptosis.37,43
Some of these effects seem mediated by direct activation of 
the essential and early transcription factor Runx2, which plays 
a pivotal role in the osteoblasts differentiation pattern,44 likely 
activating a PKA-dependent increase37,38 and/or modulating the 
expression of cyclins and cyclin-dependent kinase inhibitors 
important in both pro-survival and pro-differentiating effects 
of PTH on cells of osteoblast lineage.37,45
Further, teriparatide exerts control of replication, differen-
tiation and survival of osteoblasts progenitors by modulating 
the synthesis and release of local mediators including Wnt, 
BMPs, TGF-β, IGF-I, ﬁ  broblast growth factor-2 (FGF-2) and 
interleukin-6 (IL-6).37,46,47
Interestingly, recent data have shown that teriparatide, by 
these mechanisms of action, can counteract the GC-induced 
effects on bone cells.37
Bone levels of IGF-I decreased by GC27,32 can be stimu-
lated by PTH, leading to increasing pro-differentiating and 
pro-survival effects on osteoblats.37,46,47 More recent studies 
have also shown that PTH modulates both Wnt and sclerostin 
expression, which play important, and opposite, roles in the 
control of bone formation.37,46–48 PTH, in fact, blunts mRNA 
and protein expression of the secreted osteocytic factor 
sclerostin,37,46–49 which prevents the binding of Wnt ligands to 
their receptors, which comprise Frizzled complex with either 
LRP5 or LRP6,37,46,47,49,50 critical for bone formation.46
Additionally, GC stimulate the differentiation of stromal 
cells towards the adipocyte lineage,47,51 decreasing the 
differentiation of progenitors towards bone cell lineages and, 
thus, contributing to the disruption of bone cell homeostasis.37,46,51 
Intermittent PTH inhibits PPARγ transactivation activity, 
decreasing adipocytic differentiation and leading to an increase 
in the number of osteoblasts37,46,51 and again antagonizing the 
deleterious effects of these steroids on the skeleton.
Clinical implications of teriparatide 
in GIOP
Prophylaxis in patients receiving GC is extremely low. 
Recently published studies estimate that the proportion of 
patients receiving some form of osteoporosis prophylaxis is 
Glucocorticoids
Osteocytes Osteoblasts Osteoclasts
↓ Functions
↑ Apoptosis
↓ Differentiation
↓ Function
↑ Apoptosis
RANKL
CSF
 ↑ Genesis
↓ Apoptosis
↓ ↓ Quality ↓ ↓ Formation ↑ ↑ Resorption
Figure 1 Synthesis of glucocorticoids effects on bone cells.
Abbreviation: CSF, colony-stimulating factor; RANKL, receptor activator for nuclear factor κ B ligand.Therapeutics and Clinical Risk Management 2009:5 308
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between 30% and 62%.51 The use of bone active medication 
is extremely low among GC users with estimates of just 
1.8% of patients using bisphosphonates during the period 
of follow-up.52
Current guidelines for GIOP management recommend 
bisphosphonates, especially alendronate and risedronate, 
as ﬁ  rst-line agents for GIOP, and guidelines propose the 
preventive use of bisphosphonates early in the course of GC 
therapy in high-risk patients.53,54
More recently, efﬁ  cacy data have demonstrated that 
teriparatide is an efﬁ  cacious treatment for patients with GIOP 
compared with an approved treatment, alendronate.58–61 Due 
to the results obtained in these clinical studies, teriparatide 
has recently received an indication for GIOP and label 
indication has also been expanded.
Indeed, it is clear from the mechanisms of actions 
described above that teriparatide is, to date, the only anabolic 
molecule that can counteract the deleterious effects of 
GC on the skeleton, and thus is an efﬁ  cacious therapy for 
GIOP.57
The first interesting data on the protective role of 
teriparatide in GIOP have been published by Lane and 
colleagues, who showed, in a small pilot study, that 
teriparatide could not only block the GC-induced bone 
loss, but could even increase spine bone mineral density 
(BMD) by 12% and femoral neck BMD by a slightly lesser 
amount.58,59
Interestingly, the same authors measured BMD of the 
spine every 6 months by dual-energy X-ray absorptiometry 
(DXA) and L1 and L2 vertebrae by quantitative computed 
tomography (QCT) annually. Vertebral cross-sectional area 
(VCSA) was obtained from the QCT scans and the vertebral 
compressive strength VCSA was also calculated. After 1 
year of human PTH (1–34) treatment, VCSA signiﬁ  cantly 
increased and this result was maintained after treatment was 
discontinued. Since vertebral fracture risk is related to both 
bone size and bone mass, the authors speculated that the 
increase in vertebral size associated with human PTH (1–34) 
treatment was, at least in part, responsible for increased 
vertebral bone strength and reduction of fracture risk.59
A larger study by Saag and colleagues further demonstrated 
the efﬁ  cacy of teriparatide in GIOP.60–61 The data were derived 
from an 18-month randomized, double-blind controlled trial, 
in which teriparatide was given to women and men with 
osteoporosis (age 22–89 years) who had received GC for at 
least 3 months (prednisone equivalent, 5 mg daily or more) 
and compared with alendronate. The primary outcome was 
the change in BMD at the lumbar spine, while secondary 
outcomes included changes in hip BMD, markers of bone 
turnover, incidence of fractures and safety. The data showed 
that teriparatide blocked, as already demonstrated, the bone 
loss induced by GC, but also induced a signiﬁ  cant increase 
in BMD at the lumbar spine (7.2% ± 0.7%) by 6 months 
(p  0.001). Even more interestingly, fewer new vertebral 
fractures were present in the teriparatide group than in the 
alendronate group (0.6% vs 6.1%, p = 0.004) while the 
incidence of nonvertebral fractures was similar in the two 
groups (5.6% vs 3.7%, p = 0.36).60,61 In following studies,62 
serum levels of RANKL, OPG, IL-6, and IL-6sR were 
evaluated at baseline and thereafter for a total of 24 months. 
Teriparatide caused a rapid and signiﬁ  cant increase in serum 
RANKL within 1 month, remaining elevated throughout 
the duration of therapy. IL-6 increased signiﬁ  cantly within 
1 month, but returned to baseline levels more rapidly. In 
contrast, OPG was mildly suppressed from 6 months after 
therapy.62 These data further support the hypothesis that 
human PTH (1–34) ﬁ  rst stimulates osteoblast maturation 
and function, which in turn leads to osteoclast activation 
with a consequent gradual rebalancing of bone formation 
and resorption. The bone mass increase in speciﬁ  c sites 
might require different lengths of time, as demonstrated in 
another study which showed maximum increase in bone mass 
at the hip at least 6 to 12 months after the PTH treatment 
discontinuation.63
The 36-month data, an extension of this published study, 
was presented at the 2008 meeting of the America Society 
of Bone and Mineral Research at Montreal, conﬁ  rming the 
increase in BMD, the persistence of the signiﬁ  cant decrease 
in fracture risk and, also, the safety of this therapy.64 In 
particular, in this 36-month trial GIOP patients treated with 
teriparatide had greater increases in BMD at the lumbar spine 
and femoral neck and fewer new vertebral fractures compared 
with patients treated with alendronate. Furthermore, 
teriparatide treatment, usually prescribed for 24 months, was 
well tolerated in the 36-month trial.
In conclusion, the mechanism of action of this new 
anabolic agent and the clinical data demonstrate that 
teriparatide can be considered a safe and highly promising 
therapeutic approach for GIOP.
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